Effect of Mask Dead Space and Occlusion of Mask Holes on Delivery of Nebulized Albuterol

REFERENCES

1. 1.↵
   1. Martinez FD,
   2. Wright AL,
   3. Taussig LM,
   4. Holberg CJ,
   5. Halonen M,
   6. Morgan WJ

   . Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995;332(3):133-138.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Schweich PJ,
   2. Smith KM,
   3. Dowd MD,
   4. Walkley EI

   . Pediatric emergency medicine practice patterns: a comparison of pediatric and general emergency physicians. Pediatr Emerg Care 1998;14(2):89-94.

   OpenUrlPubMedWeb of Science
3. 3.↵
   1. McCulloh RJ,
   2. Smitherman SE,
   3. Koehn KL,
   4. Alverson BK

   . Assessing the impact of national guidelines on the management of children hospitalized for acute bronchiolitis. Pediatr Pulmonol 2013 [Epub ahead of print] doi:10.1002/ppul.22835.
4. 4.↵
   1. Mellon M,
   2. Leflein J,
   3. Walton-Bowen K,
   4. Cruz-Rivera M,
   5. Fitzpatrick S,
   6. Smith JA

   . Comparable efficacy of administration with face mask or mouthpiece of nebulized budesonide inhalation suspension for infants and young children with persistent asthma. Am J Respir Crit Care Med 2000;162(2 Pt 1):593-598.

   OpenUrlPubMedWeb of Science
5. 5.↵
   1. Georgitis JW,
   2. McWilliams B,
   3. Cruz-Rivera M,
   4. Fitzpatrick S,
   5. Smith JA

   . Effective once-daily administration of budesonide inhalation suspension by nebulizer with facemasks or mouthpieces for persistent asthma in infants and young children. Pediatr Asthma Allergy Immunol 2001;15(1):3-13.

   OpenUrlCrossRef
6. 6.↵
   1. Lowenthal D,
   2. Kattan M

   . Facemasks versus mouthpieces for aerosol treatment of asthmatic children. Pediatr Pulmonol 1992;14(3):192-196.

   OpenUrlPubMedWeb of Science
7. 7.↵
   1. Kishida M,
   2. Suzuki I,
   3. Kabayama H,
   4. Koshibu T,
   5. Izawa M,
   6. Takeshita Y,
   7. et al

   . Mouthpiece versus facemask for delivery of nebulized salbutamol in exacerbated childhood asthma. J Asthma 2002;39(4):337-339.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Sangwan S,
   2. Gurses BK,
   3. Smaldone GC

   . Facemasks and facial deposition of aerosols. Pediatr Pulmonol 2004;37(5):447-452.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Geller DE

   . Clinical side effects during aerosol therapy: cutaneous and ocular effects. J Aerosol Med 2007;20(Suppl 1):S100-S108; discussion S109.

   OpenUrlPubMed
10. 10.↵
    1. Chavez A,
    2. McCracken A,
    3. Berlinski A

    . Effect of face mask dead volume, respiratory rate, and tidal volume on inhaled albuterol delivery. Pediatr Pulmonol 2010;45(3):224-229.

    OpenUrlPubMed
11. 11.↵
    1. Shah SA,
    2. Berlinski AB,
    3. Rubin BK

    . Force-dependent static dead space of face masks used with holding chambers. Respir Care 2006;51(2):140-144.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Mundt C,
    2. Sventitskiy A,
    3. Cehelsky JE,
    4. Patters AB,
    5. Tservistas M,
    6. Hahn MC,
    7. Juhl G,
    8. Devincenzo JP

    . Assessing modeled CO₂ retention and rebreathing of a facemask designed for efficient delivery of aerosols to infants. ISRN Pediatr 2012;2012:721295.

    OpenUrlPubMed
13. 13.↵
    1. Bauer A,
    2. McGlynn P,
    3. Bovet LL,
    4. Mims PL,
    5. Curry LA,
    6. Hanrahan JP

    . The influence of breathing pattern during nebulization on the delivery of arformoterol using a breath simulator. Respir Care 2009;54(11):1488-1492.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Waldrep JC,
    2. Dhand R

    . Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Deliv 2008;5(2):114-119.

    OpenUrlCrossRefPubMed